StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Axsome Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 93.2%. For fiscal 2025 it was 92.6%, against 91.4% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202592.6%+1.2
FY2024Dec 31, 202491.4%+1.0
FY2023Dec 31, 202390.4%+0.8
FY2022Dec 31, 202289.6%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202693.8%+2.8
Q1 FY2026Mar 31, 202692.3%+0.4
Q4 FY2025Dec 31, 202593.7%+2.6
Q3 FY2025Sep 30, 202593.0%+1.1
Q2 FY2025Jun 30, 202591.0%+0.3
Q1 FY2025Mar 31, 202591.9%+0.3
Q4 FY2024Dec 31, 202491.1%+1.5
Q3 FY2024Sep 30, 202491.9%+3.2
Q2 FY2024Jun 30, 202490.8%+0.6
Q1 FY2024Mar 31, 202491.6%−0.4
Q4 FY2023Dec 31, 202389.7%−0.9
Q3 FY2023Sep 30, 202388.7%+0.1
Q2 FY2023Jun 30, 202390.2%+1.3
Q1 FY2023Mar 31, 202392.0%–
Q4 FY2022Dec 31, 202290.6%–
Q3 FY2022Sep 30, 202288.6%–
Q2 FY2022Jun 30, 202288.9%–

More Axsome Therapeutics figures

See a number that looks wrong?